Thematic review series : The Pathogenesis of Atherosclerosis An interpretive history of the cholesterol controversy , part V : The discovery of the statins and the end of the controversy 1

The first four reviews in this series (Steinberg, D. 2004. J. Lipid Res. 45: 1583–1593; Steinberg, D. 2005. J. Lipid Res. 46: 179–190; Steinberg, D. 2005. J. Lipid Res. 46: 2037–2051; Steinberg, D. 2006. J. Lipid Res. 47: 1–14) traced the gradual accumulation of evidence, evidence of several different kinds, supporting the lipid hypothesis. They tracked the history from Anitschkow's 1913 classic work on the cholesterol-fed rabbit model to the breakthrough 1984 Coronary Primary Prevention Trial, the first large, randomized, double-blind primary intervention trial showing that decreasing blood cholesterol (using cholestyramine) significantly reduces coronary heart disease events. At that point, for the first time, decreasing blood cholesterol levels became an official national public health goal. Still, only a small fraction of patients at high risk were getting appropriate cholesterol-lowering treatment, and a number of important clinical questions remained unanswered. This final review in the series traces the early studies that led to the discovery of the statins and briefly reviews the now familiar large-scale clinical trials demonstrating their safety and their remarkable effectiveness in reducing coronary heart disease morbidity and mortality.

[1]  D. Steinberg Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part IV: The 1984 Coronary Primary Prevention Trial ends it—almost1 , 2006, Journal of Lipid Research.

[2]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[3]  A. Gotto Over‐the‐counter statins and cardiovascular disease prevention: Perspectives, challenges, and opportunities , 2005, Clinical pharmacology and therapeutics.

[4]  R. Bentley The Development of Penicillin: Genesis of a Famous Antibiotic , 2005, Perspectives in biology and medicine.

[5]  D. Steinberg Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. , 2005, Journal of lipid research.

[6]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[7]  Michael S. Brown,et al.  A tribute to Akira Endo, discoverer of a “Penicillin” for cholesterol , 2004 .

[8]  D. Steinberg Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy: part I Published, JLR Papers in Press, April 21, 2004. DOI 10.1194/jlr.R400003-JLR200 11 Based in part on The Cholesterol Wars, a book in preparation. , 2004, Journal of Lipid Research.

[9]  H. Büller,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[10]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[11]  J. Mckenney,et al.  Treatment of High-Risk patients with ezetimibe plus simvastatin Co-Administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals , 2004 .

[12]  Richard M. Moe,et al.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. , 2004, Journal of the American College of Cardiology.

[13]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[14]  H. Brewer,et al.  High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[15]  M. Davidson Efficacy of Simvastatin and Ezetimibe in Treating Hypercholesterolemia In a recent editorial published in JACC , 2022 .

[16]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[17]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[18]  S. Goodman Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy , 1999, Annals of Internal Medicine.

[19]  Steven Goodman Toward Evidence-Based Medical Statistics. 2: The Bayes Factor , 1999, Annals of Internal Medicine.

[20]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[21]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[22]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[23]  J. Tobert Statin therapy and CHD , 1996, The Lancet.

[24]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[25]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[26]  G. Hansson,et al.  Immune mechanisms in atherosclerosis. , 1994, Coronary artery disease.

[27]  J. Huttunen,et al.  The Helsinki Heart Study: an 8.5‐year safety and mortality follow‐up , 1994, Journal of internal medicine.

[28]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[29]  A. Endo,et al.  The discovery and development of HMG-CoA reductase inhibitors. , 1992, Journal of lipid research.

[30]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[31]  R Peto,et al.  Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. , 1991, BMJ.

[32]  D. Steinberg,et al.  The cholesterol controversy is over. Why did it take so long? , 1989, Circulation.

[33]  A. Endo Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors , 1988, Klinische Wochenschrift.

[34]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[35]  M. Brown,et al.  Appearance of crystalloid endoplasmic reticulum in compactin-resistant Chinese hamster cells with a 500-fold increase in 3-hydroxy-3-methylglutaryl-coenzyme A reductase. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Mabuchi,et al.  Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981. , 1981, Atherosclerosis. Supplements.

[37]  R Monaghan,et al.  Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Fears,et al.  The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. , 1980, Atherosclerosis.

[39]  A. Endo,et al.  Therapeutic effects of ML-236B in primary hypercholesterolemia. , 1980, Atherosclerosis.

[40]  Endo Akira,et al.  Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals , 1979 .

[41]  Y. Tsujita,et al.  Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase , 1979, Lipids.

[42]  Y. Tsujita,et al.  Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1979, Atherosclerosis.

[43]  M. Oliver Cholesterol, coronaries, clofibrate and death. , 1978, The New England journal of medicine.

[44]  M. Brown,et al.  Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. , 1978, The Journal of biological chemistry.

[45]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[46]  M. Kuroda,et al.  Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activity , 1976, Atherosclerosis. Supplements.

[47]  Y. Tsujita,et al.  ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. , 1976, The Journal of antibiotics.

[48]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[49]  J. Fine Letter: Bacteraemic shock. , 1974, Lancet.

[50]  G. Mills,et al.  The distribution and composition of serum lipoproteins in eighteen animals. , 1971, Comparative biochemistry and physiology. B, Comparative biochemistry.

[51]  J Cornfield,et al.  The Bayesian outlook and its application. , 1969, Biometrics.

[52]  J. Avigan,et al.  Deposition of desmosterol in the lesions of experimental atherosclerosis. , 1962, Lancet.

[53]  J. Avigan,et al.  Identification of 24-dehydrocholesterol in the serum of patients treated with MER-29. , 1960, Progress in cardiovascular diseases.

[54]  R. D. Mackenzie,et al.  Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). , 1959, Archives of biochemistry and biophysics.

[55]  J. Avigan,et al.  Effects of δ4-Cholestenone in Animals and in Man , 1958, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[56]  R. E. Peterson,et al.  Inhibition of Adrenocortical Steroid Secretion by Δ4-Cholestenone , 1958 .

[57]  G. S. Boyd,et al.  Effect of phenylethylacetic acid and its amide (hyposterol) on the circulating lipids and lipoproteins in man. , 1957, Lancet.

[58]  G. Tomkins,et al.  Use of Δ4-Cholestenone to Reduce the Level of Serum Cholesterol in Man , 1957, Science.

[59]  D. Steinberg,et al.  Failure of Alpha‐Phenylbutyrate and Beta‐Phenylvalerate in Treatment of Hypercholesterolemia , 1957, Circulation.

[60]  A KEYS,et al.  Phenyl butyramide and the serum cholesterol concentration in man. , 1957, Metabolism: clinical and experimental.

[61]  D. Steinberg,et al.  INHIBITORS OF CHOLESTEROL BIOSYNTHESIS AND THE PROBLEM OF HYPERCHOLESTEROLEMIA , 1956, Annals of the New York Academy of Sciences.

[62]  D. Steinberg,et al.  Inhibition of Lipid Synthesis by Alpha-Phenyl-N-Butyrate and Related Compounds , 1955, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[63]  J. Cottet,et al.  [Therapeutic study of a synthetic hypocholesterolemic agent: phenyl-ethyl-acetic acid]. , 1954, La Presse medicale.

[64]  G. Tomkins,et al.  Cholesterol synthesis by liver. IV. Suppression by steroid administration. , 1953, The Journal of biological chemistry.

[65]  J. Cottet,et al.  [Hypocholesterolemic property of sodium phenylethylacetate (22 TH) in the rat]. , 1953, Bulletin de l'Academie nationale de medecine.

[66]  A. Daemmrich Medicine, Science, and Merck , 2004 .

[67]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[68]  I.,et al.  CHOLESTEROL SYNTHESIS BY LIVER , 2003 .

[69]  S. Yusuf MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[70]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[71]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[72]  W. Roberts Safety of fenofibrate--US and worldwide experience. , 1989, Cardiology.

[73]  H. Mabuchi,et al.  Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. , 1981, The New England journal of medicine.

[74]  Y. Tsujita,et al.  Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. , 1979, Biochimica et biophysica acta.

[75]  A. Brown,et al.  Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. , 1976, Journal of the Chemical Society. Perkin transactions 1.

[76]  D. Steinberg Chemotherapeutic Approaches to the Problem of Hyperlipidemia , 1962 .

[77]  J. Avigan,et al.  Mechanism of action of MER-29, an inhibitor of cholesterol biosynthesis. , 1960, Biochemical and biophysical research communications.

[78]  R. E. Peterson,et al.  Inhibition of adrenocortical steroid secretion by delta 4-cholestenone. , 1958, Science.

[79]  G. Tomkins,et al.  [Use of delta 4-cholestenone to reduce the level of serum cholesterol in man]. , 1957, Science.